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Abstract
Background: Squamous cell carcinoma (SCC) of the external auditory canal
(EAC) is a rare disease, which is commonly classified with the modified
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Pittsburgh classification. Our aim was to evaluate the predictive performance
of this classification in relation to disease-free survival (DFS).
Methods: We examined retrospective data from a nationwide Dutch cohort
study including patients with primary EAC SCC. These data were combined
with individual patient data from the literature. Using the combined data, the
predictive performances were calculated using the c-index.
Results: A total of 381 patients were included, 294 for clinical and 281 for the
pathological classification analyses. The c-indices of the clinical and the patho-
logical modified Pittsburgh classification predicting DFS were 0.725 (0.668-0.782)
and 0.729 (0.672-0.786), respectively.
Conclusion: The predictive performance of the modified Pittsburgh classification
system as such appears to be acceptable to predict the DFS of EAC SCC. Other fac-
tors need to be added to a future model to improve the predicted performance.
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1 | INTRODUCTION
Primary carcinoma of the external auditory canal (EAC)
is a rare disease with an estimated incidence of 1 to
5 cases per million people per year.1-3 Among these
tumors, squamous cell carcinoma (SCC) is the most com-
mon histologic type.1,2,4 EAC SCC can be extensively
invasive to the temporal bone, where critical anatomical
structures are located. Because it is such a locally aggres-
sive disease that may metastasize, it is associated with a
poor prognosis and a high recurrence rate.4,5 The 5-year
disease-free survival (DFS) of EAC SCC is 29% to 83%,
depending on the tumor classification.6-9
The treatment options for EAC SCC consist of sur-
gery, radiotherapy, chemotherapy, or combinations of
these. The choice of treatment depends on the classifica-
tion of the tumor. However, the published studies pro-
vide various conclusions on the best treatment and are of
limited value due to the small study sample and the use
of different tumor classification systems. An adequate
and uniform tumor classification system is not only
essential to evaluate the various treatments, but also to
use it as a support tool for deciding on the optimal treat-
ment and predicting the prognosis of these patients.
Although there is an international standardized stag-
ing system for EAC SCC, which has been accepted by the
American Joint Committee on Cancer (AJCC),10 the mod-
ified Pittsburgh classification is currently one of the most
commonly used tumor classifications for EAC SCC.11-14
Both classification systems include four T-classifications
(T1-T4). However, the AJCC classification is mainly based
on the diameter of the tumor and the modified Pittsburgh
classification on the erosion of anatomical structures by
the tumor. Several studies have shown that the modified
Pittsburgh classification distinguishes in overall survival
(OS) between the four T-classifications.8,11,13,15-19 As
(local) recurrent or residual disease can have a serious
impact on the patients quality of life, DFS should be con-
sidered a more clinically relevant outcome measurement
for EAC SCC. However, the predictive potential of the
Pittsburgh classification to predict the DFS of individual
patients with EAC SCC has not yet been evaluated in a
large study sample. This is crucial before implementing a
classification system as predictive tool in clinical practice.
The primary aim of this retrospective study is to evalu-
ate the predictive performance of the modified Pittsburgh
classification by comparing the DFS outcome of each T-
classification, using Kaplan-Meier analyses. The predictive
performance of the modified Pittsburgh classification was
also analyzed in a multivariable Cox regression model,
including the T-classification and nodal status as predictors.
To pursue this aim, we established a Dutch nationwide
database, reviewed the literature systematically and com-
bined our nationwide database with the individual patient
data of existing retrospective studies for statistical analyses.
2 | METHODS AND MATERIALS
2.1 | Data collection for the
national data
A nationwide cohort study was conducted on patients
who were treated curatively for their primary EAC SCC
3610 NABUURS ET AL.
in one of the eight Dutch head and neck oncological cen-
ters (Radboud University Medical Center; Amsterdam
University Medical Center; Netherlands Cancer
Institute—Antoni van Leeuwenhoek; Erasmus Medical
Center; University Medical Center Groningen; Leiden
University Medical Center; Maastricht University Medi-
cal Center; University Medical Center Utrecht). Two
nationwide coding systems (ICD-code, “International Sta-
tistical Classification of Diseases and Related Health
Problems” and PALGA, “Pathologisch-Anatomisch
Landelijk Geautomatiseerd Archief”) were used to obtain
data of patients who were diagnosed with SCC of the
EAC, temporal bone or middle ear. Thereafter, the diag-
nosis was verified manually by checking the imaging and
pathological results carefully by CN. Patients were
excluded if they received palliative care for their primary
EAC SCC; the site of the origin was not the EAC, tempo-
ral bone or middle ear; the histologic subtype was not
SCC; or if the medical records were too limited to classify
the tumor. Patients were also excluded if they were
treated by local resection with local application of
5-fluorouracil or if they did not receive surgery, in order
to improve the homogeneity of the data. In order to
increase the database on this rare subject as much as pos-
sible and assuming that the improved treatment tech-
niques over the years do not significantly affect the
outcome, no inclusion or exclusion criteria were applied
to specified dates of diagnosis.
From the patients included, the data were obtained
retrospectively. All clinical and pathological staging was
done according to the modified Pittsburgh classification.
11 The clinical TNM-classification was based on clinical
exam reports and imaging results and the pathological T-
and N-classifications were adjusted if necessary based on
the operative reports and pathological results of the tem-
poral bone resection specimens.
Approval was obtained from the medical ethics com-
mittee of Radboud University Medical Center (number
2017-3397); participating centers complied with their
local medical ethics committee requirements.
2.2 | Data collection for the individual
patient data from the existing literature
To complement our cohort, we also obtained individual
patient data of existing studies identified by a systematic
review of the literature. Details of the protocol of this sys-
tematic review were registered on PROSPERO (registra-
tion number: CRD42017073053) and it can be accessed
at http://www.crd.york.ac.uk/PROSPERO/display_record.
php?ID=CRD42017073053.
A systematic literature search was conducted between
24 July 2017 and 31 August 2017 in PubMed, EMBASE,
and Cochrane Library using the terms and the synonyms
of “EAC,” “temporal bone,” “middle ear,” “SCC,” and
“survival.” Two authors, CN and NL, independently
screened the title and abstract of the retrieved articles to
identify studies meeting the inclusion criteria. Thereafter,
full texts of the remaining articles were screened by CN
and NL. Discrepancies were solved by discussion and
consensus. We included studies of patients with primary
SCC of the EAC, temporal bone or middle ear. The other
inclusion criteria were that the studies also have reported
the tumor classification or the required information in
order to classify, according to the modified Pittsburgh
classification, treatment strategy, type of resection, and
the occurrence of and time to a recurrence. Studies that
were not clear on which patients had primary EAC SCC,
that were not clear whether the TNM classification was
based on clinical results or adjusted on pathological
results, that did not present clear outcomes for individual
patients, or that were written in languages other than
Dutch or English, were excluded. In order to ensure that
the data reported in the literature did not overlap with
data from the Dutch nationwide cohort, we excluded
studies including patients treated in a Dutch center.
There were no inclusion or exclusion criteria on specified
dates of publication or dates of treatment in order to gain
a sample as large as possible. Patients were excluded if
they did not receive surgery or were treated with pallia-
tive intent in order to improve the homogeneity of
the data.
Some authors presented data of individual patients in
their paper itself. If this was incomplete or the study did
not provide the individual patient data, the authors were
contacted by electronic mail to ask for their raw data. If
the authors did not respond directly or after reminders
resulting in incomplete individual patient data, the study
concerned was excluded. If a part of the study population
met the inclusion criteria, only the individual patient's
data of these subjects were extracted.
2.3 | Statistical analysis
The predicting performance of the modified Pittsburgh
classification was examined in the combined sample,
including patients in the Dutch nationwide database and
those obtained from previously published retrospective
studies. Database consisted of the following variables:
gender, age, facial nerve paralyses, cT-classification, pT-
classification, cN-classification, pN-classification, clinical
suspected lymph node metastasis, pathological proven
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lymph node metastasis, treatment strategy, surgical treat-
ment, surgical technique, parotidectomy, neck dissection,
radiotherapy, chemotherapy, surgical margins, outcome,
recurrence/residual, DFS, DFS outcome in months, OS,
OS outcome in months, and follow up.
All analyses were performed separately for the clini-
cal and pathological TNM classification. Most of the stud-
ies obtained from the systematic literature search
presented either only the clinical or the pathological
tumor classification, but not both classifications. The
individual patient data containing only the clinical classi-
fication were only used for the statistical analysis of the
clinical classification. The individual patient data con-
taining only the pathological classification were only
used for the statistical analysis of the pathological
classification.
In order to evaluate the predictive performance of the
modified Pittsburgh classification consisting of the T-, N-
and M-classifications, a Cox proportional hazard model
was fitted with these classifications as fixed covariates
and DFS as primary outcome. DFS was defined as the
time in months from the start of treatment for EAC SCC
until recurrence. The DFS of residual diseases were con-
sidered as zero months. Patients were censored at the
moment of their last visit, when they died not due to
EAC SCC or when they were lost to follow-up. Cox pro-
portional hazard models were also created with overall
survival as outcome. OS was defined as the time in
months from the start of treatment for EAC SCC until
death caused by any reason. Patients were censored at
the time of their last visit or when they were lost to
follow-up. However, the subgroups per N-classification
appeared to be too small to analyze, so the presence or
absence of lymph node metastasis (N0 vs N+, respec-
tively) as such was used for statistical analyses instead of
separate N-classifications. Because only patients treated
with curative intent were included for this study, every
tumor included was classified as a clinical and pathologi-
cal M0. As a consequence, this variable was excluded as
covariate in our statistical analysis.
First, the raw data were explored by graphically pre-
senting the DFS per T-classification and the presence of
lymph node metastasis using the Kaplan-Meier survival
curves. The differences between the 5-year DFS outcome
across the T-classifications were analyzed using the log-
rank test. The log-rank test was also used to analyze the
difference between the 5-year DFS outcome between the
presence and absence of lymph node metastasis. These
analyses were performed using the available raw data.
Thereafter, missing data were imputed by multiple
imputation in order to prevent inefficient analyses and
biased estimates of the associations investigated using
Cox regression analyses. The multiple imputation was
performed using the “mice” package (version 2.46.0) in
the R software version 3.4.3 (R Project for Statistical
Computing).20 This method assumes that data are miss-
ing at random. Data were missing in 16 of the 24 variables
(range of 2.38%-36.39%) in the dataset containing only
subjects who had at least the clinical tumor classification.
In the dataset containing only subjects who had at least
the pathological tumor classification, data were missing
in 14 of the 24 variables (range of 0.36%-30.96%). Vari-
ables with more than 15% of missing data were the path-
ological T-classification and pathological lymph node
metastasis for the database including patients with clini-
cal classification. For the database including patients
with pathological classification database, these variables
were the clinical T-classification and clinical suspected
lymph node metastasis. Separate multiple imputations
were performed for the clinical and for the pathological
classification data, but using the same technique: we used
all variables (including information about the treatment,
baseline variables and outcomes) to predict the missing
values in 10 imputed datasets based on 10 iterations and
10 multiple imputations. The pooled multiple imputed
data were used to develop mixed effect Cox proportional
hazard regressions including individual T-classifications
(as fixed covariate), the presence of lymph node metasta-
sis (as fixed covariate), and the studyID (included centers
and studies, as random effect) on the 5-year DFS and
5-year OS.
To evaluate the predictive performance of our fitted
model the concordance index (c-index) was calculated as
is common in the field of prediction modeling. The
imputed data were used to calculate this c-index. A c-
index >0.70 was considered as a sufficient predictive per-
formance and a c-index >0.80 as an adequate predictive
performance.21
All statistical analyses were performed in R version
3.4.3 (R Project for Statistical Computing).20 In all ana-
lyses, a probability (P) value <.05 was considered statisti-
cally significant.
3 | RESULTS
3.1 | Results from national data
In total, 289 patients were diagnosed with primary EAC
SCC between 1975 and 2017. Of these patients,
103 patients were excluded because they were not
treated with curative intent (n = 68), were treated by
local resection with local application of 5-fluorouracil
(n = 25), or did not receive surgery (n = 10). Finally,
186 patients were included for this study. The mean
age was 65.9 years; 48.4% of the study population was
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male and 51.6% was female; 39.2% of the tumors was
classified as a pT4; 15.6% had pathologically proven
lymph node metastasis; 58 T-classifications were
adjusted based on operative reports and pathology
results; the median follow-up was 34 months with a
minimum of 1 month and maximum of 344 months;
and 68 patients had residual disease or recurrence.
Table 1 shows the patient's characteristics per medical
center.
3.2 | Results from literature study and
using the individual patient data from the
existing literature
Our search strategy identified 1490 studies. Figure 1
shows the flowchart of the inclusion and exclusion of
studies. After applying these inclusion and exclusion
criteria, 11 studies were included with a total of
432 patients. Table 2 provides general information of the
articles included. Of the 432 patients, 195 patients met
the inclusion criteria and remained for further analyses.
Of the patients included 44 patients experienced residual
disease or recurrence. The characteristics of the studies
included are provided in Table 3. All studies included
were retrospective studies published between 2000 and
2017. Patients of the studies included were treated
between 1978 and 2014. Although the follow-up of the
studies were in general relatively short with a median of
34.8 months (1-211 months) and not all studies described
both the clinical and pathological tumor classifications
(2 of 11 studies), the individual patient's data of the stud-
ies included contained the necessary data for our statisti-
cal analyses.
3.3 | Patient characteristics
In total 381 patients, 186 patients from the Dutch nation-
wide database and 195 patients from the individual
patient data of 11 previous studies, with primary EAC
SCC were included for this study. Mean age of the com-
bined data was 64.5 year; the gender distribution was 44%
female, 45% male, and 11% unreported gender; approxi-
mately 29.2%, 11.4%, 21.0%, and 38.4% of the tumors were
classified as pT1, pT2, pT3, and pT4 respectively; 16% of
the tumors were diagnosed with pN+; the median follow-
up was 34 months with a range of one to 344 months; and
112 patients had residual disease or recurrence (Table 3).
Details of the treatment strategies and surgical tech-
niques are summarized in Table 4. All tumors were
mainly treated by surgery in combination with radiother-
apy within the Dutch nationwide database tumors.
Within the individual patient data from previous studies
included the cT1- and cT2-classified tumors were mainly
treated by surgery only and cT3- and cT4-classified
tumors by surgery in combination with radiotherapy or
chemoradiation. The most frequently applied surgical
technique was the lateral temporal bone resection (LTBR),
but some of the T1-classified tumors were operated by
local resection instead of LTBR. T3- and T4-classified
tumors were usually operated by LTBR in combination
with a parotidectomy and/or neck dissection.
3.4 | Predictive performance of the
modified Pittsburgh classification
As shown in the Kaplan-Meier survival curves (Figure 2A,
B) the 5-year DFS of cT1-, cT2-, cT3-, and cT4-classified















1 52 68.5 (38-91) 20 (38.5) 19 4 7 22 5 (9.6) 35 (1-344)
2 40 69 (29-90) 21 (52.5) 8 6 13 13 9 (22.5) 28 (3-267)
3 10 67.5 (37-81) 5 (50) 4 2 2 2 4 (40) 51 (8-344)
4 9 68 (40-77) 8 (88.9) 1 1 3 4 2 (22.2) 29 (8-62)
5 18 63.5 (39-78) 8 (44.4) 3 2 4 9 3 (16.7) 39 (4-235)
6 24 64.5 (49-89) 15 (62.5) 9 2 2 11 3 (12.5) 56 (1-209)
7 10 72.5 (49-85) 4 (40) 1 0 6 3 2 (20) 13 (4-116)
8 23 68 (49-84) 9 (39.1) 7 2 5 9 1 (4.3) 41 (4-122)
Total 186 67 (29-91) 90 (48.4) 52 (28%) 19 (10%) 42 (23%) 73 (39%) 29 (15.6) 34 (1-344)
Abbreviations: FU, follow-up.
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tumors were 84.2%, 83.5%, 64.5%, and 41.8%, respectively,
and of the pT1-, pT2-, pT3-, and pT4-classified tumors
88.9%, 76.7%, 66.2%, and 39.0%, respectively. However, the
log-rank tests showed that the overall DFS outcomes
between T1- and T2-classified tumors (P = .84 for clinical
classification, P = .37 for pathological classification) and
between T2- and T3-classified tumors (P = .096 for clinical
classification, P = 0.47 for pathological classification) were
not statistically significantly different from each other.
The log-rank tests of the overall DFS outcomes between
the remaining T-classifications were statistically signifi-
cant (all P’s < .05).
The Kaplan-Meier curves also showed that cN+ had a
poorer 5-year DFS outcome compared with cN0, 36.7% vs
67.9%, respectively. This result was comparable for pN+
compared to pN0, 45.4% vs 65.1% DFS outcome, respectively.
The log-rank tests showed that the DFS outcomes of the cN
+ and pN+ were statistically significantly poorer compared
to cN0 or pN0, P < .001 and P < .009, respectively.
The effect of the T-classifications and presence of
lymph node metastasis on the DFS outcome and the
OS outcome were analyzed in a mixed-effects Cox pro-
portional hazard regression in order to calculate the
c-index. The c-index of the clinical classification to pre-
dict the DFS was 0.713 (95% CI = 0.656-0.770) and of
the pathological classification 0.742 (CI = 0.685-0.799)
(Table 5). The c-index predicting the OS outcome of the
clinical classification was 0.668 (CI = 0.609-0.727) and
of the pathological classification 0.734 (0.675-0.793)
(Table 6).
4 | DISCUSSION
In this retrospective study, we primarily aimed to evalu-
ate the performance of the modified Pittsburgh classifica-
tion to predict the DFS outcome of patients with primary
EAC SCC. It turned out that DFS was statistically signifi-
cantly different between all T-classifications except for
T2- vs T1- and T2- vs T3-classified tumor and the predic-
tive performances were acceptably, but with a relatively
broad confidential interval of the hazard ratios.
FIGURE 1 Flowchart of studies [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 2 Characteristics of studies included






study Reason of exclusion
Choi et al22 August 1989 to March
1996




1994 to 2006 17 7 2 recurrences; 8 patients were diagnosed
with other histologic types of tumors
Lassig et al13 January 1995 to April
2007
30 13 14 patients with tumors of auricle/
preauricular/parotid/or postauricular; 3
tumors were unresectable and we
assumed that these patients were not
treated with curative intent
Matoba et al24 January 1999 to
December 2014
25 10 3 patients with auricle tumor; 4 patients
had other histologic type; 1 tumor was a
recurrence; 7 patients were treated
without surgery
Moody et al11 1978 to 1998 32 32
Moore et al25 1990 to 2007 35 17 The published article included 15 patients
with tumors consisting of other
histologic type than SCC; we received
data of 21 patients with SCCa and we
excluded 3 patients because these tumors
were located at auricle; 1 patient because
the tumor was a recurrence of a parotid
tumor
Morita et al16 April 1997 to March
2015
66 34 32 patients did not receive surgery
Morris et al26 1994 to 2010 72 19 We received data of 81 patientsa of which
61 patients were excluded because of the
following: 41 patients with other tumor
site than middle ear, external auditory
canal, or temporal bone; 14 patients with
other histologic type; 6 patients who
were treated previously for a tumor in
the same region; and in 1 patient
radiotherapy was stopped early due to




January 1998 to March
2004
25 11 1 patient had previous radiotherapy at the
tumor location; 2 patients were treated




January 1979 to July
2000
20 10 10 patients had tumors with other





89 31 We received data of 92 patientsa; 21
patients had tumors at other locations;
21 patients had other histologic type
than SCC; 19 patients were treated
previously for a tumor in the same
region
Abbreviations: SCC, squamous cell carcinoma.
aThe author sent us data from the patients included in their published studies as well as data from patients who were included in their data-
base after the studies were published.
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It is difficult to integrate our results with previously
described results. First of all, although some studies
describe the DFS as clinical outcome, they combined the
T1- and T2-classified tumors as early tumors and/or the
T3- and T4-classified tumors as advanced tumors.5,8,19 In
addition, many published studies do not describe the
DFS as the primary outcome by default, but rather the
overall survival.11,15,30,31 For two main reasons, we
decided deliberately to analyze primarily the DFS and
not the OS. First of all, we think that DFS is clinically
more relevant compared to overall survival as outcome,
because (local) recurrence or residual disease can have a
serious impact on the patients quality of life. Further-
more, OS outcome might be influenced by more con-
founders such as comorbidities and age compared to DFS
outcome. In order to compare our results with other stud-
ies, we calculated the OS as secondary outcome.
Although the OS outcomes of pT1-pT4-classified tumors
based on our combined database (2-year OS of 92%, 74%,
76%, 45%; 5-year OS of 84%, 66%, 67%, 35%; respectively)
are not fully comparable with the studies of Moody et al
(2-year OS of T1-T4 classified tumors: 100%, 80%, 50%,
and 7%, respectively)11 and Chi et al (5-year OS year OS
of T1-T4 classified tumors: 100%, 67%, 21%, and 14%,
respectively),15 all these results show that the OS out-
comes decrease if the T-classification rises. The differ-
ences in OS found in our study compared with these
previously published studies might be due in part to the
smaller number of participants in the previous studies.
However, the predictive performance expressed in a c-
























Choi et al22 11 60 (35-67) 7 (63.6) C 2 3 2 4 0 (0) 29 (6-136)
Kawahara
et al23
7 62 (41-69) 4 (57.1) C 0 0 1 6 NR 62.4 (8-88)
Lassig et al13 13 70 (31-88) 7 (53.8) P 4 3 2 4 4 (30.8) 48 (1-150)
Matoba et al24 10 62.5
(57-76)
5 (50) P 3 2 2 3 3 (30) 33.5
(10-196)
Moody et al11 32 72 (42-92) NR P 7 5 6 14 4 (12.5) 20 (5-211)
Moore et al25 17 62 (27-83) 8 (47.1) P 6 1 4 6 3 (17.6) 49 (5-173)
Morita et al16 34 65 (29-86) 17 (50) C 13 9 8 4 5 (14.7) 37.5
(4-112)
Morris et al26 19 64 (32-85) 13 (68.4) C 4 0 3 2 1 (5.3) 29 (6-188)
P 9 0 3 7 2 (10.5)
Nakagawa
et al27
11 61 (46-80) 6 (54.5) C 0 1 3 3 1 (14.3) 48 (4-84)
P 1 2 0 1 0 (0)
Nyrop and
Grøntved28
10 NR NR C 6 0 1 3 0 (0) 32 (6-141)
Wierzbicka
et al29




186 67 (29-91) 90 (48.4) C 57 18 40 70 23 (12.4) 34.0
(1-344)
P 52 19 42 73 29 (15.6)
Total 381 64.5
(20-92)
171 (44.9) C (n = 294) 82 (28%) 33 (11%) 62 (21%) 117 (40%) 35 (11.9) 34.0
(1-344)
P (n = 281) 82 (29%) 32 (11%) 59 (21%) 108 (38%) 45 (16)
aThe number of patients from the original studies included in the current analyses. Some individual patient's data within these studies
included did not meet the inclusion criteria and were excluded, for example, recurrences, adenoid cystic carcinoma, or basal cell carcinoma.
FU, follow-up. NR, not reported.
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FIGURE 2 Kaplan-Meier disease-free survival curves of the clinical and pathological T-classification based on the modified Pittsburgh
classification and presence of lymph node disease cT, clinical T-classification; cN0, no clinical suspected lymph node disease; cN+, clinical
suspected lymph node disease; pN0, no pathological lymph node disease; pN+, pathological proven lymph node metastasis; pT, pathological
T-classification [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 5 Mixed-effects Cox proportional hazard regression predicting disease-free survival
Hazard ratio 95% confidential interval P value
Clinical modified Pittsburgh classificationa (n = 294)
cT1 Reference
cT2 1.285 0.452 to 3.649 .64
cT3 2.603 1.250 to 5.422 .011*
cT4 4.798 2.515 to 9.155 <.001***
cN0 Reference
cN+ 1.698 1.016 to 2.838 .044*
C-index 0.713 (0.656-0.770)
Pathological modified Pittsburgh classificationb (n = 281)
pT1 Reference
pT2 1.714 0.564 to 5.208 .340
pT3 1.906 0.828 to 4.386 .130
pT4 4.519 2.106 to 9.695 <.001***
pN0 Reference
pN+ 1.135 0.649 to 1.983 .660
C-index 0.742 (0.685-0.799)
Abbreviations: N0, no lymph node metastasis; N+ = lymph node metastasis.
aStudyID as random effect: χ2 = 0.74; P = .27.
bStudyID as random effect: χ2 = 20.04; P = .01*.
*Statistically significant (P < .05). ***Statistically significant (P < .001).
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index or area under the curve of the modified Pittsburgh
classification itself has not yet been studied, as far as we
know. This study shows that the c-indices for predicting
the OS outcome of EAC SCC were about 0.7 (0.67-0.73), a
little less compared to the c-index for predicting the DFS
outcome. This might be explained by the other con-
founders influencing the OS outcome. If the modified
Pittsburgh classification is to be used as a prognostic tool
in clinical settings to predict the survival outcome of
patients with EAC SCC, an evaluation such as our study
is important.
It could be argued whether predictive performances
of 0.713 (95% CI = 0.656-0.770) and of 0.742
(CI = 0.685-0.799) for DFS are acceptable to use it as a
tool in clinical settings or not. An adequate discrimina-
tion of a prediction tool can inform clinicians which
treatment will give the most optimal survival outcome.
However, models with inadequate discrimination perfor-
mance can have major adverse impacts. The modified
Pittsburgh classification was not originally designed as a
prediction model: it is used to classify the tumor and to
decide the treatment for this cancer as with other tumor
classification systems. By inaccurately classifying a tumor
too low or too high, there is a risk of under- or over-
treatment resulting in potentially higher risk of recurrent
disease, unnecessary harm, and even death. Our Dutch
nationwide database showed that 58 of the 168 clinical T-
classifications were adjusted based on operative reports
and pathology results. The clinical T-classification was
based on diagnostic imaging results. However, not all
patients received a magnetic resonance scan in addition
to the computed tomography, especially not the patients
who were diagnosed before the year 2000. Studies
showed that magnetic resonance imaging is a valuable
diagnostic tool to classify EAC SCC, because it is more
sensitive to demarcate the soft tissue extent of the
tumor.32,33 The adjusted pathological classification may
have affected the slight difference between the c-indices
for predicting the DFS of the clinical and pathological
classification. Even though this study shows that the
modified Pittsburgh classification discriminates accept-
ably, a higher c-index may be necessary to use the classi-
fication as a predictor.
The limitations in the predictive performance of the
modified Pittsburgh classification system as shown in this
study might be caused by the T4-classified tumors. The
modified Pittsburgh classification does not discriminate
T4-classified tumors with different directions of tumor
invasion (anterior, posterior, medial, lateral, superior, or
inferior). Therefore, the treatment and the DFS outcome
TABLE 6 Mixed-effects Cox proportional hazard regression predicting overall survival
Hazard ratio 95% confidential interval P value
Clinical modified Pittsburgh classificationa (n = 294)
cT1 Reference
cT2 0.904 0.364 to 2.249 .830
cT3 1.426 0.779 to 2.609 .250
cT4 2.421 1.431 to 4.094 <.001***
cN0 Reference
cN+ 1.439 0.847 to 2.445 .180
C-index 0.668 (0.609-0.727)
Pathological modified Pittsburgh classificationb (n = 281)
pT1 Reference
pT2 1.533 0.716 to 3.281 .27
pT3 1.548 0.809 to 2.964 .19
pT4 4.006 2.355 to 6.817 <.001***
pN0 Reference
pN+ 1.728 1.084 to 2.754 .021*
C-index 0.734 (0.675-0.793)
Abbreviations: N0, no lymph node metastasis; N+, lymph node metastasis.
aStudyID as random effect: χ2=3.26; P = .28.
bStudyID as random effect: χ2=18.80; P = .008*.
*Statistically significant (P < .05). ***Statistically significant (P < .001).
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may differ for tumors within this same T-classification.
Lavieille et al34 proposed in 1997 a new subclassification
for the T4-classified tumors, taking into account the
direction of the tumor invasion: (T4a) extracranial exten-
sion, (T4b) intrapetrous bone and extradural extension,
and (T4c) meningeal or intradural involvement.34
Zanoletti et al also suggested subclassifying the
T4-classified tumors according to the direction of the
invasion of the tumor. Their results showed that tumors
spreading anteriorly (parotid space and preauricular
region) had a significant higher DFS outcome (87.5%)
compared to T4-classified EAC SCC spreading elsewhere
(posterior, superior, inferior, or medial; DFS outcome
was 8.3%).19 To improve the predictive performance of
the modified Pittsburgh classification, a future model
might be needed that incorporates a T4-subclassification.
In addition, the literature already showed that surgi-
cal margins are also an important prognostic factor and
that positive surgical margins result in significant poorer
survival outcome compared to negative surgical margins.
The Pittsburgh classification and surgical margins were
significant predictors for the prognosis of patients with
EAC SCC according to the study of Yin et al.35 Morris
et al also reported surgical margins as one of the stron-
gest predictors of survival.26 Consequently, to optimize
the predictive performance for the DFS outcome of
patients with EAC SCC, a predictor like surgical margins
might need to be added in a future prediction model.
Several limitations to the present study need to be
acknowledged. By combining our nationwide database
with available individual patient data from prior studies,
the sample size for this study was increased and became
the largest published cohort study on EAC SCC to our
knowledge. Unfortunately, we were unable to include all
published studies found in our search. Although we con-
tacted the authors of the concerned studies for additional
information, not all the authors could deliver the
required data. Collecting prospective data for such a rare
disease is not realistic, therefore retrospective data were
used. However, one should realize the disadvantages of
retrospective data. One of the disadvantages is that 9 of
the 11 studies included gave information on clinical or
pathological classification only, which made it difficult to
combine these data with the nationwide database
resulting in two separate databases either including the
clinical or pathological classification. When using the
individual data of previously published studies, there
must be awareness for the risk of false-positive results by
multiple testing. Furthermore, not all individual patient
data included information we required, this contributed
to missing data up to about 30% for some variables. How-
ever, we tried to correct for these missing values by
multiple imputation. Even though our combined data
resulted in a relatively large database on EAC SCC, the
subgroups were still small. The subgroups for N-
classification were even too small for adequate statistical
analyses. This is caused by the fact that only 12% to 16%
of the patients in this study with EAC SCC had lymph
node metastasis. In order to include lymph node metasta-
ses in our prediction model, we used the presence and
absence of lymph node disease in the Cox regression
model instead of separate N-classifications. Larger data-
bases are needed for adequate statistical analyses on
EAC SCC.
The various chosen treatment per T-classification
might also affect the DFS outcome. Because the sub-
groups per treatment strategy of this retrospective study
were too small, the effect of the chosen treatment on the
DFS outcome has not been statistically corrected in the
Cox regression models. Another limitation of this study is
that there is a chance that within the T3 and T4 tumors
of the individual patient data derived from prior studies,
patients were treated without curative intent and there-
fore received less aggressive treatments, resulting in
worse outcomes compared to similar patients who were
treated curatively. Patients who were known to have
received palliative treatment were excluded. However, it
was not clear from all patients whether they were consid-
ered incurable or not. In spite of its limitations, the study
certainly adds to our understanding of the predictive per-
formance of the modified Pittsburgh classification.
5 | CONCLUSION
The predictive performance of the modified Pittsburgh
classification system on its own seems acceptable to pre-
dict the DFS for patients with EAC SCC. However, we
also indicated room for improvement. We suggest to add
a revised T4-classification of the modified Pittsburgh clas-
sification and other predicting factors, such as surgical
margins, in a future prediction model in order to improve
the predicted performance in clinical practice and to use
it as a treatment decision support tool for patients with
EAC SCC.
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